MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
National Research Corporation Interest Expense 2011-2026 | NRC
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense National Research Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 862 K | 1.21 M | 1.67 M | 1.81 M | 2.09 M | 1.51 M | 82 K | 190 K | 220 K | 305 K | 397 K | 541 K | 629 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.09 M | 82 K | 886 K |
Quarterly Interest Expense National Research Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.46 M | 1.03 M | 899 K | - | 706 K | 555 K | 605 K | - | -12 K | -2 K | 241 K | - | 288 K | 318 K | 317 K | - | 413 K | 423 K | 432 K | - | 451 K | 450 K | 465 K | - | 510 K | 533 K | 570 K | - | 544 K | 439 K | 8 K | - | 18 K | 23 K | 27 K | - | 38 K | 36 K | 85 K | - | 52 K | 57 K | 63 K | - | 76 K | 78 K | 81 K | - | 91 K | 101 K | 117 K | - | 134 K | 140 K | 142 K | - | 155 K | 156 K | 169 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.46 M | -12 K | 300 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M |  USA |
 |
Danaher Corporation
DHR
|
-56 M | $ 237.64 | 1.12 % | $ 174 B | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 12.15 | -5.81 % | $ 345 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 23.25 | -0.66 % | $ 250 M |  China |
 |
DexCom
DXCM
|
20.3 M | $ 66.95 | -2.16 % | $ 25.8 B | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.59 | -0.94 % | $ 2.02 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
106 K | $ 6.12 | - | $ 180 M | USA |
 |
IQVIA Holdings
IQV
|
670 M | $ 243.33 | 0.06 % | $ 44.1 B | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 39.59 | -0.76 % | $ 1.1 B | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Natera
NTRA
|
9.32 M | $ 234.65 | -2.05 % | $ 23.1 B | USA |
 |
CareDx, Inc
CDNA
|
1.34 M | $ 17.02 | -1.16 % | $ 915 M | USA |
 |
Celcuity
CELC
|
2.11 M | $ 107.43 | 2.63 % | $ 4.24 B | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Pacific Biosciences of California
PACB
|
14.3 M | $ 1.95 | -4.66 % | $ 495 M | USA |
 |
Anixa Biosciences
ANIX
|
500 K | $ 3.41 | -0.29 % | $ 109 K | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 102.13 | 0.34 % | $ 18.9 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 27.84 | -0.2 % | $ 842 M | USA |
 |
QIAGEN N.V.
QGEN
|
-739 K | $ 48.32 | -0.27 % | $ 10.8 B |  Niderland |
 |
RadNet
RDNT
|
24.9 M | $ 77.42 | -1.22 % | $ 5.65 B | USA |
 |
Guardant Health
GH
|
-42.6 M | $ 110.18 | 1.32 % | $ 13.5 B | USA |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 141.01 | -3.31 % | $ 22.4 B | USA |
 |
Charles River Laboratories International
CRL
|
-16.5 M | $ 220.64 | 2.38 % | $ 11.3 B | USA |
 |
Thermo Fisher Scientific
TMO
|
12 M | $ 620.69 | 2.34 % | $ 237 B | USA |
 |
Trinity Biotech plc
TRIB
|
6.75 M | $ 0.73 | -1.13 % | $ 61.9 M |  Irlanda |
 |
Twist Bioscience Corporation
TWST
|
-903 K | $ 35.58 | 2.42 % | $ 2.13 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
30 M | $ 175.1 | -1.49 % | $ 19.4 B | USA |
|
Biodesix
BDSX
|
8.26 M | $ 5.46 | -2.15 % | $ 708 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
208 M | $ 252.61 | -0.81 % | $ 21.2 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 183.13 | -2.7 % | $ 15.1 B | Irlanda |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 715.47 | 0.43 % | $ 59 B | USA |
 |
Lantheus Holdings
LNTH
|
37.2 M | $ 67.98 | 0.19 % | $ 4.7 B | USA |
 |
Agilent Technologies
A
|
81 M | $ 148.92 | 2.17 % | $ 45.3 B | USA |
 |
Biomerica
BMRA
|
367 | $ 2.75 | -4.84 % | $ 6.32 M | USA |
 |
Bioventus
BVS
|
1.29 M | $ 8.02 | 0.25 % | $ 502 M | USA |